Pyxis Oncology announced on May 24 that it acquired Apexigen, Inc. for $16 million.
Founded in 2010, Apexigen, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology.
Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates and immunotherapies. It is funded by the Longwood Fund, a Boston-based venture capital firm.
This acquisition was announced nearly a year after Apexigen went public by a merger with Brookline Capital Acquisition Corp.
According to data captured in the LevinPro HC database, this acquisition represents the 61st Biotechnology transaction of the year. This is a 27% increase from the year before (January 1, 2022, through May 24, 2022) when 48 Biotechnology transactions were reported.
